Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
J Psychopharmacol ; 37(10): 1003-1010, 2023 10.
Article in English | MEDLINE | ID: mdl-37466276

ABSTRACT

BACKGROUND: Due to the inflammatory factors in the pathophysiology of schizophrenia, Pentoxifylline, as anti-inflammatory medication, seems to improve the symptoms of schizophrenia. This study aims to evaluate the efficacy of Pentoxifylline as an adjunctive therapy on cognitive deficits and symptoms of schizophrenia. METHODS: This randomized double-blind placebo-controlled clinical trial was conducted on 52 patients diagnosed with chronic schizophrenia. All patients were divided into two, treatment and control groups. They received a 400 mg dose of Pentoxifylline and the placebo in the treatment and control groups, respectively, twice a day for 8 weeks. Then, they were tested with the Positive and Negative Syndrome Scale (PANSS), Wisconsin Card Sorting Test (WCST), digit span, Stroop test, and Rey Auditory and Verbal Learning Test at baseline and the end of the weeks 4 and 8. Data analysis was done by Kolmogorov-Smirnov test, t-test, Mann-Whitney test, chi-square test, and generalized estimating equation model. RESULTS: After analyzing the data, it was revealed that the positive symptoms of PANSS, the number of errors in the incongruent Stroop test, and reaction time in the congruent Stroop test were significantly lower in the treatment group (p < 0.05). Moreover, the number of categories of WCST was significantly higher in the treatment group (p < 0.05). There was no statistically significant difference in other parameters between the control and treatment groups (p > 0.05). CONCLUSIONS: As evidenced by the results of this study, Pentoxifylline can help alleviate schizophrenia cognitive deficits and can reduce psychotic symptoms. Therefore, it can potentially be useful for schizophrenia treatment.


Subject(s)
Antipsychotic Agents , Cognitive Dysfunction , Pentoxifylline , Schizophrenia , Humans , Schizophrenia/complications , Schizophrenia/drug therapy , Pentoxifylline/therapeutic use , Cognitive Dysfunction/drug therapy , Cognition , Double-Blind Method , Treatment Outcome , Drug Therapy, Combination , Psychiatric Status Rating Scales
2.
Iran J Psychiatry ; 17(2): 243-246, 2022 Apr.
Article in English | MEDLINE | ID: mdl-36262758

ABSTRACT

Objective: Synesthesia is a unique experience with an unclear mechanism. The clinical condition usually presents when a sensation stimulates other senses. While more than 150 types of synesthesia have been reported; however, some types are considered uncommon, and co-occurrence of these rare types of synesthesia are rare. In the present report, we described a case of synesthesia with experience of pain and orgasm in color. Method : A 31-year old healthy male presented with visual equity changes during orgasm. In addition, he described a color-pain sensation every time he experienced severe chest pain during his childhood. None of these sensations negatively affected his daily or sexual life. Based on the patient's history, a possible diagnosis of synesthesia was made and further clinical evaluations were performed. Results: The patient did not have any color vision abnormalities or problems in solving Hooper visual organization test, bells test, Rey complex figure test, card sorting test, and Trail making tests. The Brief Male Sexual Inventory did not reveal any sexual dysfunction. Therefore, regarding the patient's experiences without any visual disturbance and absence of any underlying diseases, the diagnosis of synesthesia was made. Conclusion: The present report demonstrates coexistence of a rare form of synesthesia as orgasm to color with specific pain to color synesthesia. In contrast to previous reports, our case demonstrated color orgasm as a type of synesthesia that might not negatively affect sex life in men.

4.
Can J Physiol Pharmacol ; 98(4): 236-242, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32228235

ABSTRACT

Obsessive-compulsive disorder (OCD) is a chronic psychiatric disorder, of unknown etiology, that affects 2.5% of the population. An appropriate therapeutic response to conventional treatment is seen. Some studies use augmentative treatment by antipsychotics, glutamatergic, lithium, buspirone, and others agents to improve the therapeutic response. In this study, we aimed to evaluate the efficacy and tolerability of aripiprazole and quetiapine as augmentative treatments in patients with selective serotonin reuptake inhibitor (SSRI) refractory OCD. The OCD patients were initially treated for 12 weeks with a SSRI. If after 12 weeks their Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score was more than 16, they were randomly assigned to either the aripiprazole or the quetiapine augmentation group for an additional 12 weeks. There were no significant differences in age, sex, education, marital status, or score of Y-BOCS and Clinical Global Impression-Severity Scale (CGI-S) between groups (p > 0.05) at the outset of the study. Significant differences were noted after 1 month when compared with results at 2, 3, and 4 months in both groups (p < 0.001). Both quetiapine and aripiprazole may be effective and well-tolerated augmentative agents in the treatment of SSRI-refractory OCD. Because of positive results, aripiprazole may be considered more effective and may have a more rapid onset in terms of therapeutic response.


Subject(s)
Antipsychotic Agents/therapeutic use , Aripiprazole/therapeutic use , Obsessive-Compulsive Disorder/drug therapy , Quetiapine Fumarate/therapeutic use , Selective Serotonin Reuptake Inhibitors/therapeutic use , Serotonin/metabolism , Adult , Drug Therapy, Combination/methods , Female , Humans , Male , Obsessive-Compulsive Disorder/metabolism , Single-Blind Method
5.
J Psychopharmacol ; 33(11): 1364-1376, 2019 11.
Article in English | MEDLINE | ID: mdl-31556787

ABSTRACT

BACKGROUND: The relationship between depression and increased oxidative stress is well known. DNA damage by oxidation factors is an important cause of the aging process in psychiatric disorders. AIMS: Owing to the scarcity of human studies and high inconsistencies in studies of the effects of antidepressants on DNA damage, the current study was undertaken to investigate the effects of depression and its treatment on DNA damage. METHODS: In a 15-week open-label study of citalopram (n = 25) and sertraline (n = 20), levels of DNA damage were measured by comet assay, proinflammatory (Interlukin-6 (IL-6)) and oxidative DNA damage (8-hydroxy-2'-deoxyguanosine (8-OHdG)) markers by ELISA, and gene expression of base excision repair enzymes (8-oxoguanine glycosylase (OGG1) and poly (ADP)-ribose polymerase-1 (PARP1)) by quantitative real-time polymerase chain reaction in healthy control patients (n = 14), with depression at the baseline and the same patients after week 15. RESULTS: DNA damage, 8-OHdG, IL-6 and expression of PARP1 were elevated in patients with depression compared with the healthy controls (p < 0.001). Selective serotonin reuptake inhibitor (SSRI) therapy could significantly reduce the depression score (p < 0.01), DNA damage (p < 0.001), as well as 8-OHdG and IL-6 (p < 0.0001). Nevertheless, the expression of PARP1 and OGG1 showed no significant changes after treatment. CONCLUSIONS: This is the first study on the effect of SSRIs on the DNA damage and some of the repair enzymes in depression. Based on the results, depression can cause increased DNA damage. This damage is followed by activation of compensatory mechanisms whereby the expression of DNA damage repair enzymes is elevated. Finally, the treatment of psychiatric disorder by antidepressants can lower the level of oxidative DNA damage.


Subject(s)
Citalopram/administration & dosage , DNA Damage/drug effects , Depressive Disorder/drug therapy , Selective Serotonin Reuptake Inhibitors/administration & dosage , Sertraline/administration & dosage , Adult , Case-Control Studies , Citalopram/pharmacology , Comet Assay , DNA Glycosylases/genetics , Depressive Disorder/genetics , Female , Humans , Male , Middle Aged , Oxidative Stress/drug effects , Poly (ADP-Ribose) Polymerase-1/genetics , Selective Serotonin Reuptake Inhibitors/pharmacology , Sertraline/pharmacology
6.
J Psychol ; 152(4): 226-236, 2018 May 19.
Article in English | MEDLINE | ID: mdl-29630459

ABSTRACT

The growing rate of smoking cigarettes among the youths necessitates examining its contributing factors. Accordingly, we aimed to compare smoking and nonsmoking university students in their attachment styles, perceived loneliness, and psychological well-being. To this end, we recruited 100 current smokers and 100 nonsmoking students by using a convenience sampling method from Shahid Beheshti University, Tehran, Iran. All participants completed the Adult Attachment Scale, Loneliness Scale, and General Health Questionnaire. Data analysis indicated that compared to nonsmokers, smokers had a more anxious attachment style and they felt lonelier. Moreover, current results showed that smokers suffered from higher rates of psychological problems than nonsmokers. These results suggest that smoking is influenced by a set of psychological factors and therefore, prevention and treatment programs targeting these factors may be effective in reducing the rate of smoking cigarettes among university students.


Subject(s)
Loneliness/psychology , Smoking/psychology , Social Behavior , Students/psychology , Universities , Adolescent , Adult , Anxiety/psychology , Female , Humans , Iran , Male , Surveys and Questionnaires , Young Adult
7.
Psychiatry Res ; 247: 125-129, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27888682

ABSTRACT

Suicidal behaviors are serious public health problems. The prominent association of mood disorders with suicide, along with the renaissance of the spectrum concept of psychiatric disorders in the recent decades, prioritizes the investigation of temperament variants in suicidal individuals. This study aimed to explore the relationship between affective temperaments and nonviolent suicide attempts. We administered Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego Auto questionnaire (TEMPS-A) to 141 (27 males and 114 females) consecutive self-poisoning non-lethal suicide attempters at a Medical Toxicology Center and a sex and age matched group of healthy individuals (28 males, 112 females). Female suicide attempters scored significantly higher in depressive, cyclothymic, irritable, and anxious temperaments compared with female controls, whereas male cases' scores were significantly higher in depressive and anxious subscales compared with control males. Except for hyperthymic temperament which did not reveal any significant effects, depressive (OR: 11.5), cyclothymic (OR: 3.8), irritable (OR: 2.3), and anxious (OR: 8.8) temperaments were predictors for nonviolent suicide attempts. Therefore, this study replicated the evidence for the strong association of depressive temperament with suicide attempts. The hyperthymic temperament appeared to have neither protective nor predisposing influence. Further studies are needed to identify the role of this independent temperament.


Subject(s)
Affective Symptoms/psychology , Mood Disorders/psychology , Poisoning/psychology , Suicide, Attempted/psychology , Temperament , Adult , Case-Control Studies , Cross-Sectional Studies , Female , Humans , Male , Surveys and Questionnaires , Young Adult
8.
Psychiatry Res ; 229(1-2): 394-400, 2015 Sep 30.
Article in English | MEDLINE | ID: mdl-26205631

ABSTRACT

Involvement of personality traits in susceptibility to suicidal behaviour has attracted considerable research interest over the past decades. This study was motivated by reports that emotionality may play a potentially confounding role in the association between the personality profile and suicidal behaviour. We assessed the association between personality traits, as measured using the Temperament and Character Inventory (TCI), and suicidal behaviour, while controlling for the effects of Affective Temperaments, measured using the Temperament Evaluation of the Memphis, Pisa, Paris and San Diego auto-questionnaire (TEMPS-A) in a sample of 140 consecutive self-poisoning nonlethal suicide (SNS) attempters admitted to the Emergency Toxicology Clinic, comparing them with a sample of 140 age and sex matched healthy controls. After controlling for Affective Temperaments, the temperament dimension of Novelty Seeking (NS) and the character dimensions of Self-directedness and Self-transcendence remained significantly associated with SNS attempts. NS, in particular, was most consistently and uniquely associated with suicidal behaviour. The present study conveys the difficulty in disentangling the personality profile of SNS attempters from their emotionality. We conclude that the risk associated with certain personality traits is often entirely mediated by Affective Temperaments and few dimensions independently contribute to the risk of self-poisoning nonlethal suicidal behaviour.


Subject(s)
Affect , Personality , Suicidal Ideation , Suicide, Attempted/psychology , Temperament , Adolescent , Adult , Case-Control Studies , Cross-Sectional Studies , Female , Healthy Volunteers , Humans , Male , Personality Inventory , Poisoning , Surveys and Questionnaires , Young Adult
9.
Iran J Immunol ; 4(1): 38-43, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17652842

ABSTRACT

BACKGROUND: Major Depression Disorder (MDD) is a common disorder with prevalence of 15% among men and up to 25% among women. In recent years the association of immune system alterations and MDD has been investigated. Assessments of immunologic and inflammatory responses in these patients enhance our knowledge of the etiology and pathogenesis of this disease. OBJECTIVE: To investigate the changes in immunoglobulin and cytokine serum levels and lymphocyte subsets in patients with MDD. METHODS: We studied 37 adult patients with MDD, diagnosed based on DSM-IV diagnostic criteria, and 15 healthy controls matched with the patients. Plasma concentration of interleukin-4 (IL-4), IL-10, TNF alpha, and IFN gamma were measured by ELISA and serum immunoglobulins by SRID. Total number of NK cells (CD16 and CD56), B cells (CD19), and T cells (CD8, CD4, and CD3) were determined by flow cytometry. RESULTS: We found no significant differences in plasma concentration of IL-4, IL-10, TNF-alpha, IFN-gamma, and immunoglobulins as well as total number of NK cells, B cells, and T cells between major depressed patients and healthy control subjects. CONCLUSION: We conclude that in our patients, there were no significant differences in immune system activity between MDD patients and controls.


Subject(s)
Depressive Disorder, Major/immunology , Immune System/immunology , Adult , Animals , B-Lymphocytes/immunology , Cross-Sectional Studies , Cytokines/blood , Depressive Disorder, Major/blood , Female , Flow Cytometry , Humans , Immunoglobulins/blood , Iran , Killer Cells, Natural/immunology , Male , Reference Values , T-Lymphocytes/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...